clinical trial · NCT06120075
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Advanced CancerAB801Docetaxel
brief summary
The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a recommended AB801 dose for expansion.
started
Jan 19, 2024
primary completion
Nov 1, 2026
completion
Nov 1, 2026
last updated
Jul 1, 2026
official title
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol